Mental Health News and Research

Latest Mental Health News and Research

QRxPharma receives date for US pain drug launch, pending approval

Australian pain-relief drug developer QRxPharma (QRX) has announced today that they have received from the US Food & Drug Adminstration.

8 Nov 2011

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

AstraZeneca and Targacept, Inc. today announced top-line results from the first of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment.

8 Nov 2011

Link between heavy methamphetamine use and schizophrenia

In the first worldwide study of its kind, scientists from Toronto's Centre for Addiction and Mental Health (CAMH) found evidence that heavy methamphetamine users might have a higher risk of developing schizophrenia.

8 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

New study questions effectiveness of current exercise referral schemes

Research commissioned by the NIHR Health Technology Assessment programme and carried out by research teams from the Peninsula College of Medicine and Dentistry (PCMD) and the Universities of Exeter (Sport and Health Sciences) and Brunel (Health Economics Research Group), has called into question the effectiveness of exercise referral schemes as they are delivered at present.

7 Nov 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex Pharmaceuticals Incorporated today announced positive interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with chronic genotype 1 hepatitis C (HCV) and human immunodeficiency virus.

7 Nov 2011

Intensive diet, exercise reduce pain and improve mobility in people with knee OA

According to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago, weight loss combined with exercise reduces pain and improves mobility in people with knee osteoarthritis.

7 Nov 2011

HHS scientists to share recent rheumatology findings at 75th ACR annual meeting

Hospital for Special Surgery physician-scientists who focus on arthritis, lupus, vasculitis and related conditions are traveling from New York City to Chicago this week to share their recent findings at the 75th Annual Scientific Meeting of the American College of Rheumatology.

7 Nov 2011

Psychological stress can trigger flares of vasculitis

In patients with a devastating form of vasculitis who are in remission, stress can be associated with a greater likelihood of the disease flaring, according to a new study by investigators at Hospital for Special Surgery.

6 Nov 2011

Earthquakes devastating in more ways than one: Review

According to a new study published Thursday in the Lancet earthquakes can be devastating during and after they have come and gone.

6 Nov 2011

Chemical breakthrough could simplify drug development process

A new chemical process developed by a team of Harvard researchers greatly increases the utility of Positron Emission Tomography (PET) in creating real-time 3-D images of chemical process occurring inside the human body.

5 Nov 2011

Incorporating mental health into agenda to ensure access to services for all

In this Lancet editorial, Giuseppe Raviola, Anne Becker and Paul Farmer, professors with the Department of Global Health and Social Medicine at Harvard Medical School, write, "Unprecedented opportunities to promote excellence and equity in health care delivery for the world's most underserved populations are upon us," but "delivery of mental health services in low-resource settings lags unacceptably and unjustly far behind that of other services."

5 Nov 2011

State roundup: Puerto Rico settles disability battle with Feds

Puerto Rico has reached an agreement with the U.S. government ending a 12-year legal battle to improve the island's health system for the mentally disabled, local justice officials said Thursday. Federal officials had accused the U.S. territory of abusing and neglecting hundreds of mentally disabled people by not providing food, medication, adequate housing, therapy or mental health care.

5 Nov 2011

IAFN to celebrate 'Forensic Nurses Week' on Nov. 7-11

"You are safe" are often the first words heard by survivors of violent acts when Forensic Nurses are present to provide care in hospitals, clinics, jails and community settings around the world. Forensic Nurses are nurses with advanced education and training, giving them the skills to deal with the immediate health care consequences of violence. On November 7-11, the International Association of Forensic Nurses (IAFN) will celebrate "Forensic Nurses Week" to recognize these nurses who provide exceptional care to victims and perpetrators of abuse and violence.

5 Nov 2011

Toxoplasma gondii directly affects production of dopamine in brain

A research group from the University of Leeds has shown that infection by the brain parasite Toxoplasma gondii, found in 10-20 per cent of the UK's population, directly affects the production of dopamine, a key chemical messenger in the brain.

5 Nov 2011

VA announces 13 new awards in 2010 Industry Innovation Competition

The Department of Veterans Affairs today announced 13 new awards in the agency's 2010 Industry Innovation Competition. The new projects will give VA an opportunity to evaluate new ways to enhance care and benefits for Veterans.

5 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

Viewpoints: Romney's plan to cut the debt; congressional squabbles on spending; spurning insurers' concerns about new labels

First, eliminate every government program that is not absolutely essential. There are many things government does that we may like but that we do not need. … For example: Repeal ObamaCare, which would save $95 billion in 2016. …Eliminate Title X family planning programs benefiting abortion groups like Planned Parenthood. … Second, return federal programs to the states where innovation, cost management and reduction of fraud and abuse can far exceed what Washington achieves. I will block grant Medicaid and workforce training, saving well over $100 billion in 2016.

5 Nov 2011

Psychotherapy could have diverse cerebral effects depending on certain genes

Problems like anxiety and depression are caused by psychological and environmental factors, and are known to be influenced by genetic proclivities. However, it is still not clear how each factor affects the brain's functions to induce anxious and depressive symptoms.

4 Nov 2011

Vanda third quarter total revenues increase to $8.0 million

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2011.

4 Nov 2011

Mental Health News and Research

Latest Mental Health News and Research

QRxPharma receives date for US pain drug launch, pending approval

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

Link between heavy methamphetamine use and schizophrenia

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

New study questions effectiveness of current exercise referral schemes

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Intensive diet, exercise reduce pain and improve mobility in people with knee OA

HHS scientists to share recent rheumatology findings at 75th ACR annual meeting

Psychological stress can trigger flares of vasculitis

Earthquakes devastating in more ways than one: Review

Chemical breakthrough could simplify drug development process

Incorporating mental health into agenda to ensure access to services for all

State roundup: Puerto Rico settles disability battle with Feds

IAFN to celebrate 'Forensic Nurses Week' on Nov. 7-11

Toxoplasma gondii directly affects production of dopamine in brain

VA announces 13 new awards in 2010 Industry Innovation Competition

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Viewpoints: Romney's plan to cut the debt; congressional squabbles on spending; spurning insurers' concerns about new labels

Psychotherapy could have diverse cerebral effects depending on certain genes

Vanda third quarter total revenues increase to $8.0 million

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Mental Health News and Research

Latest Mental Health News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in